{ "Phase 1 Study of LNCB74 for Advanced Solid Tumors", "This study is testing a new treatment called LNCB74 for people with advanced solid tumors, including ovarian, breast, endometrial, biliary tract, and non-small cell lung cancers. LNCB74 is an antibody-drug conjugate (a type of targeted therapy that delivers a drug directly to cancer cells) that works through an immunotherapy mechanism. You would receive LNCB74 intravenously (into a vein) in cycles lasting 21 days. The main goals are to find out how safe LNCB74 is, what side effects it might cause, and to determine the best dose for future studies. This study is currently open to adults aged 18 and older with advanced solid tumors that cannot be removed by surgery or have spread.", "design": "This is an open-label, Phase 1 study, meaning both you and the study team will know you are receiving LNCB74. It aims to enroll 145 participants to find the safest and most effective dose.", "commitments": "You would receive LNCB74 intravenously in 21-day dosing cycles. The study will evaluate your safety and tolerability for up to 24 months.", "compensation": "Not stated in the trial record.", "follow_up": "Your safety and tolerability will be evaluated for up to 24 months after starting the study.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.